<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Preoperative assessment of bleeding risk</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Preoperative assessment of bleeding risk</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Preoperative assessment of bleeding risk</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paula James, MD, FRCPC</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark Crowther, MD, MSc</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jane Givens, MD, MSCE</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nancy A Nussmeier, MD, FAHA</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 07, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Preoperative determination of bleeding risk is critical to reducing the risk of excessive surgical bleeding. This topic discusses preoperative assessment of bleeding risk including questions to ask and indications for laboratory testing. </p><p>Separate topics discuss:</p><p class="bulletIndent1"><span class="glyph">●</span>General preoperative medical evaluation – (See  <a class="medical medical_review" href="/z/d/html/4816.html" rel="external">"Preoperative medical evaluation of the healthy adult patient"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Preoperative evaluation for anesthesia – (See  <a class="medical medical_review" href="/z/d/html/94539.html" rel="external">"Preoperative evaluation for anesthesia for noncardiac surgery"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Perioperative management of anticoagulation – (See  <a class="medical medical_review" href="/z/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>General perioperative medication management – (See  <a class="medical medical_review" href="/z/d/html/4814.html" rel="external">"Perioperative medication management"</a> and  <a class="medical medical_review" href="/z/d/html/94596.html" rel="external">"Prevention of perioperative medication errors"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">DETERMINE BLEEDING RISK</span><span class="headingEndMark"> — </span>Bleeding risk depends on the likelihood of an underlying bleeding disorder and the specific surgical procedure. </p><p class="headingAnchor" id="H3"><span class="h2">Bleeding history</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Elements of the history </strong>–<strong> </strong>The patient's personal bleeding history and family history of bleeding disorders are essential to the preoperative evaluation. Patients should be asked about:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nosebleeds</p><p class="bulletIndent2"><span class="glyph">•</span>Oral and dental bleeding</p><p class="bulletIndent2"><span class="glyph">•</span>Skin bleeding </p><p class="bulletIndent2"><span class="glyph">•</span>Whether bleeding occurred with trauma or surgery</p><p class="bulletIndent2"><span class="glyph">•</span>Gastrointestinal, urologic, and menstrual bleeding</p><p class="bulletIndent2"><span class="glyph">•</span>Obstetric bleeding, including postpartum hemorrhage</p><p class="bulletIndent2"><span class="glyph">•</span>Other sites of bleeding (muscle, joints, central nervous system, others)</p><p></p><p class="bulletIndent1">Children may not have had dental or other procedures, although parents may be aware of an unusual bleeding or bruising tendency. Absence of these "bleeding challenges" can make it more challenging to assess the likelihood of abnormal bleeding in children. (See <a class="local">'Children'</a> below.)</p><p></p><p class="bulletIndent1">The severity of past bleeding episodes should be ascertained. For example, any bleeding severe enough to require transfusions, packing, cautery, medications, or surgical exploration is considered more concerning than bleeding that resolved spontaneously or required consultation without interventions.</p><p></p><p class="bulletIndent1">A history of unexplained, refractory iron deficiency or persistent, unexplained reticulocytosis without hemolysis may suggest an underlying bleeding disorder.</p><p></p><p class="bulletIndent1">The family history of bleeding disorders is also relevant. Sometimes a formal diagnosis may not have been made, but a first-degree relative may have had significant bleeding. A diagnosis of hemophilia in a male relative is relevant for female patients because they may be a carrier with factor activity low enough to require additional treatments.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Use of bleeding assessment tool</strong> – An easy-to-use bleeding assessment tool (BAT) from the International Society of Thrombosis and Hemostasis (ISTH) that rates the severity of bleeding at these sites is available online and can be completed by a member of the clinical team in a few minutes (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fbleedingscore.certe.nl%2F&amp;token=Nn2kz6P9LalXZBakWq4EFVy%2FtKzfMxWmVZgnncoM9zqnY8WwoOfYCEf5tSBri%2Fvl&amp;TOPIC_ID=1315" target="_blank">ISTH-BAT</a>) [<a href="#rid1">1,2</a>]. </p><p></p><p class="bulletIndent1">An abnormal bleeding history is determined by a positive bleeding score [<a href="#rid3">3</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Adult female: ≥6</p><p class="bulletIndent2"><span class="glyph">•</span>Adult male: ≥4</p><p class="bulletIndent2"><span class="glyph">•</span>Child: ≥3</p><p></p><p class="bulletIndent1">Further study in adult females has shown that scores indicating abnormal bleeding vary by age [<a href="#rid4">4</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>18 to 30 years: ≥5</p><p class="bulletIndent2"><span class="glyph">•</span>31 to 51 years: ≥6</p><p class="bulletIndent2"><span class="glyph">•</span>52 to 88 years: ≥7</p><p></p><p class="bulletIndent1">More structured bleeding assessment tools have been developed and widely studied. (See  <a class="medical medical_review" href="/z/d/html/1367.html" rel="external">"Approach to the adult with a suspected bleeding disorder", section on 'Bleeding score'</a>.)</p><p></p><p class="bulletIndent1">The ISTH-BAT was developed to assess for the presence of inherited bleeding disorders, and therefore would not necessarily be useful for patients with acquired conditions such as those caused by medication or concurrent medical problems [<a href="#rid5">5</a>]. Prospective studies using this tool in the preoperative setting are ongoing. </p><p></p><p class="headingAnchor" id="H5"><span class="h2">Examination</span><span class="headingEndMark"> — </span>Physical findings that suggest a potential bleeding disorder include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Skin bleeding</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Petechiae  (<a class="graphic graphic_picture graphicRef71480" href="/z/d/graphic/71480.html" rel="external">picture 1</a>) or ecchymoses suggests thrombocytopenia or functionally deficient platelets  (<a class="graphic graphic_table graphicRef77834" href="/z/d/graphic/77834.html" rel="external">table 1</a>). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Telangiectasias may reflect underlying liver disease (spider angiomas, often present on the trunk or face)  (<a class="graphic graphic_picture graphicRef74047" href="/z/d/graphic/74047.html" rel="external">picture 2</a>) or hereditary hemorrhagic telangiectasia (HHT, with telangiectasias in the mouth and on the lips)  (<a class="graphic graphic_picture graphicRef77416" href="/z/d/graphic/77416.html" rel="external">picture 3</a>). (See  <a class="medical medical_review" href="/z/d/html/1253.html" rel="external">"Cirrhosis in adults: Etiologies, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hematomas may also be due to factor deficiencies or inhibitors against a clotting factor  (<a class="graphic graphic_table graphicRef77834" href="/z/d/graphic/77834.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Signs of collagen vascular disorders</strong> – Some forms of Ehlers-Danlos syndrome can be associated with prolonged bleeding due to an impairment in the structure of the blood vessels. These patients have hyperelasticity of the skin and hyperextendable joints. Other disorders of blood vessel structure associated with clinical bleeding, which may have associated findings on physical examination, include scurvy and Cushing's syndrome  (<a class="graphic graphic_picture graphicRef65564" href="/z/d/graphic/65564.html" rel="external">picture 4</a>). (See  <a class="medical medical_review" href="/z/d/html/14920.html" rel="external">"Clinical manifestations and diagnosis of Ehlers-Danlos syndromes"</a> and  <a class="medical medical_review" href="/z/d/html/5591.html" rel="external">"Clinical manifestations and diagnosis of hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorder"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Signs of liver disease or splenomegaly </strong>–<strong> </strong>Any obvious signs of liver disease (ascites, hepatomegaly) or splenomegaly should be evaluated further. (See  <a class="medical medical_review" href="/z/d/html/7134.html" rel="external">"Splenomegaly and other splenic disorders in adults", section on 'How to examine the spleen'</a> and  <a class="medical medical_review" href="/z/d/html/3617.html" rel="external">"Clinical manifestations and diagnosis of alcohol-associated fatty liver disease and cirrhosis"</a> and  <a class="medical medical_review" href="/z/d/html/1234.html" rel="external">"Assessing surgical risk in patients with liver disease", section on 'Screening for liver disease before surgery'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sequelae of prior bleeding</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Over time, hemarthroses can lead to joint deformities  (<a class="graphic graphic_table graphicRef77834" href="/z/d/graphic/77834.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/1310.html" rel="external">"Clinical manifestations and diagnosis of hemophilia", section on 'Late complications'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Resolving bruises may be apparent. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acquired von Willebrand syndrome (AVWS)</strong> – A heart murmur may indicate aortic stenosis or other cardiac conditions associated with AVWS. (See  <a class="medical medical_review" href="/z/d/html/110531.html" rel="external">"Acquired von Willebrand syndrome", section on 'Cardiovascular disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vitamin C deficiency/scurvy</strong> – Patients may have gingivitis, loose teeth, perifollicular purpura, and corkscrew hairs. Acquired vitamin C deficiency should be suspected in patients with prior bariatric surgery who present with a new bleeding disorder [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/z/d/html/5360.html" rel="external">"Micronutrient deficiencies associated with protein-energy malnutrition in children", section on 'Ascorbic acid'</a> and  <a class="medical medical_review" href="/z/d/html/14614.html" rel="external">"Nutritional status in patients with sustained heavy alcohol use", section on 'Vitamin C'</a> and  <a class="medical medical_review" href="/z/d/html/5367.html" rel="external">"Overview of water-soluble vitamins", section on 'Vitamin C (ascorbic acid)'</a>.)</p><p></p><p class="headingAnchor" id="H2658562134"><span class="h2">Surgical bleeding risk</span><span class="headingEndMark"> — </span>The table summarizes risk of bleeding with different procedures  (<a class="graphic graphic_table graphicRef86929" href="/z/d/graphic/86929.html" rel="external">table 2</a>). </p><p class="headingAnchor" id="H1912042750"><span class="h1">LABORATORY TESTING</span></p><p class="headingAnchor" id="H17813752"><span class="h2">Avoid routine testing in unselected individuals</span><span class="headingEndMark"> — </span>Routine coagulation testing prior to surgery is generally discouraged due to the low likelihood of finding a bleeding disorder in unselected individuals and the poor predictive value of standard coagulation tests.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach</strong> – We reserve laboratory testing for selected individuals and selected procedures with a high risk of bleeding. This includes patients with the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Known bleeding disorder.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Comorbidity likely to impair hemostasis, such as:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Active cancer or receiving cancer therapy (see <a class="local">'Cancer'</a> below)</p><p class="bulletIndent3"><span class="glyph">-</span>Liver disease or excess alcohol intake (see <a class="local">'Liver disease'</a> below)</p><p class="bulletIndent3"><span class="glyph">-</span>Chronic kidney disease (see <a class="local">'Kidney disease'</a> below) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Family history of a bleeding disorder, unless the patient was previously evaluated and determined not to have the disorder. Females who have male relatives with hemophilia may warrant testing for factor activity. (See  <a class="medical medical_review" href="/z/d/html/1310.html" rel="external">"Clinical manifestations and diagnosis of hemophilia", section on 'Bleeding in females/carriers'</a> and  <a class="medical medical_review" href="/z/d/html/1310.html" rel="external">"Clinical manifestations and diagnosis of hemophilia", section on 'Obstetric considerations'</a>.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Receiving an anticoagulant. (See  <a class="medical medical_review" href="/z/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Surgery with a high risk of bleeding or a high risk of severe harm should bleeding occur:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Neurosurgery</p><p class="bulletIndent3"><span class="glyph">-</span>Open cardiac surgical procedures</p><p class="bulletIndent3"><span class="glyph">-</span>Major vascular surgical procedures</p><p></p><p class="bulletIndent2">Blood tests for hemostasis are routinely available prior to these procedures; they should be closely reviewed and any abnormalities evaluated. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Guidelines</strong> – Our approach is similar to a 2008 systematic review and guideline from the British Committee for Standards in Haematology, which concluded that [<a href="#rid7">7</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The positive predictive value for coagulation testing is low.</p><p class="bulletIndent2"><span class="glyph">•</span>Routine coagulation testing should not be performed.</p><p class="bulletIndent2"><span class="glyph">•</span>Bleeding history should be obtained, including specific questions about prior surgical procedures, trauma, antithrombotic medications, and family history.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>If the bleeding history is negative, coagulation testing is not indicated.</p><p class="bulletIndent3"><span class="glyph">-</span>If the bleeding history is positive, further testing is indicated based on the specific findings. </p><p></p><p class="bulletIndent1">This is also similar to guidelines from other societies, including the American Society of Anesthesiologists, a Choosing Wisely initiative, and a guideline from the Association of Anaesthetists of Great Britain and Ireland, which recommend not using routine preoperative laboratory testing in the absence of a clinical indication. (See  <a class="medical medical_review" href="/z/d/html/94539.html" rel="external">"Preoperative evaluation for anesthesia for noncardiac surgery", section on 'Preoperative testing'</a>.)</p><p></p><p class="bulletIndent1">It differs from a 2009 guideline from the Italian Society for Haemostasis and Thrombosis (SISET), which recommends routine testing of the prothrombin time (PT), activated partial thromboplastin time (aPTT), and platelet count in all children and adults undergoing surgery or invasive procedures other than endoscopy [<a href="#rid8">8</a>]. The rationale was based on the possibility of identifying a bleeding disorder, especially in children, and the need for baseline testing should complications of the procedure arise.</p><p></p><p class="bulletIndent1">Guidelines for specific populations propose specific testing, such as in children with cancer [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evidence from observational studies</strong> – Randomized trials in unselected populations comparing routine testing versus no testing are extremely limited. Most evidence comes from small observational studies, often retrospective. These have generally shown poor predictive value of the PT and aPTT for bleeding, as summarized in various guidelines and review articles [<a href="#rid7">7,8,10</a>]. </p><p></p><p class="bulletIndent1">Examples include: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A 2023 systematic review of nearly 50,000 eye surgeries from four randomized trials and five observational studies found that routine complete blood count (CBC) and coagulation testing did not reduce complications [<a href="#rid11">11</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Studies of other types of testing that could predict bleeding risk have failed to identify a useful test. Examples of tests evaluated include:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>von Willebrand factor (VWF) antigen [<a href="#rid12">12</a>]</p><p class="bulletIndent3"><span class="glyph">-</span>Thromboelastography (TEG) [<a href="#rid13">13,14</a>]</p><p class="bulletIndent3"><span class="glyph">-</span>Fibrinogen [<a href="#rid13">13</a>]</p><p class="bulletIndent3"><span class="glyph">-</span>Platelet function analyzer (PFA-100) [<a href="#rid15">15</a>] (see  <a class="medical medical_review" href="/z/d/html/4433.html" rel="external">"Platelet function testing", section on 'PFA-100'</a>) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The template bleeding time is widely discussed in the context of bleeding risk around surgery. This test is highly unreliable, has largely been abandoned by experts in the field, and has no role in the routine assessment of perioperative bleeding risk. </p><p></p><p class="headingAnchor" id="H932941200"><span class="h2">Testing for people with a suspected bleeding disorder</span><span class="headingEndMark"> — </span>If the family history, patient history, and/or physical examination suggests a bleeding disorder, appropriate screening tests should be performed.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Start with PT, aPTT, and platelet count</strong> – Generally, people with a suspected bleeding disorder are tested with coagulation studies (PT and aPTT) and CBC with platelet count. (See  <a class="medical medical_review" href="/z/d/html/1367.html" rel="external">"Approach to the adult with a suspected bleeding disorder", section on 'Laboratory evaluation'</a> and  <a class="medical medical_review" href="/z/d/html/1367.html" rel="external">"Approach to the adult with a suspected bleeding disorder", section on 'Subsequent testing based on initial clinical and laboratory features'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Test for known familial disorders</strong> – If there is a known familial bleeding disorder, specific testing for that disorder would be appropriate along with the above testing.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Follow up abnormal results</strong> – Subsequent testing is based on results of the initial testing  (<a class="graphic graphic_table graphicRef79969" href="/z/d/graphic/79969.html" rel="external">table 3</a>). A prolonged aPTT requires further investigation but does not necessarily imply the presence of a bleeding disorder. (See  <a class="medical medical_review" href="/z/d/html/1367.html" rel="external">"Approach to the adult with a suspected bleeding disorder", section on 'Positive bleeding history and abnormal screening tests'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Testing for individuals with positive bleeding history and normal initial testing</strong> – Some bleeding disorders will have normal PT, aPTT, and platelet count since coagulation factor activity levels generally must be &lt;20 to 40 percent to prolong the PT or aPTT. Individuals with a positive bleeding history and normal initial testing may require specific factor levels, von Willebrand disease (VWD) screening tests, platelet function testing, and/or other tests, depending on the bleeding pattern and family history  (<a class="graphic graphic_table graphicRef77834" href="/z/d/graphic/77834.html" rel="external">table 1</a>). </p><p></p><p class="bulletIndent1">Evaluation of these patients should be undertaken in concert with an expert clinical center and after careful review of the patient's family history of bleeding. (See  <a class="medical medical_review" href="/z/d/html/1367.html" rel="external">"Approach to the adult with a suspected bleeding disorder", section on 'Positive bleeding history and normal initial testing'</a>.)</p><p></p><p>Supporting evidence comes from observational studies that have found positive bleeding history in up to 19 percent of patients screened by history and physical examination [<a href="#rid16">16,17</a>]. Some of the larger studies that evaluated laboratory testing found abnormal testing in &lt;1 percent of individuals with a negative history [<a href="#rid18">18</a>]. </p><p class="headingAnchor" id="H1806512524"><span class="h1">SELECTED PATIENT POPULATIONS</span></p><p class="headingAnchor" id="H1779756122"><span class="h2">Known bleeding disorder or antithrombotic agent</span><span class="headingEndMark"> — </span>Preoperative planning should involve the patient's hematologist or other specialist managing their disorder or anticoagulation. Patients with known bleeding disorders will often have written plans for hemostatic management with them in case of severe or unexpected bleeding.</p><p>Separate topics discuss general management considerations:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>von Willebrand disease (VWD)</strong> – (See  <a class="medical medical_review" href="/z/d/html/1372.html" rel="external">"von Willebrand disease (VWD): Treatment of major bleeding and major surgery"</a> and  <a class="medical medical_review" href="/z/d/html/122618.html" rel="external">"von Willebrand disease (VWD): Treatment of minor bleeding, use of DDAVP, and routine preventive care"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immune thrombocytopenia (ITP)</strong> – (See  <a class="medical medical_review" href="/z/d/html/6677.html" rel="external">"Initial treatment of immune thrombocytopenia (ITP) in adults", section on 'Surgery or delivery'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemophilia</strong> – (See  <a class="medical medical_review" href="/z/d/html/1314.html" rel="external">"Treatment of bleeding and perioperative management in hemophilia A and B", section on 'Elective surgery'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anticoagulants</strong> – (See  <a class="medical medical_review" href="/z/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anti-platelet agents</strong> – (See  <a class="medical medical_review" href="/z/d/html/4814.html" rel="external">"Perioperative medication management", section on 'Medications affecting hemostasis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neuraxial anesthesia</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Antithrombotic medications </strong>– (See  <a class="medical medical_review" href="/z/d/html/14930.html" rel="external">"Neuraxial anesthesia/analgesia techniques in the patient receiving anticoagulant or antiplatelet medication"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Thrombocytopenia</strong> – (See  <a class="medical medical_review" href="/z/d/html/4469.html" rel="external">"Adverse effects of neuraxial analgesia and anesthesia for obstetrics", section on 'Neuraxial analgesia and low platelets'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Impaired coagulation</strong> – (See  <a class="medical medical_review" href="/z/d/html/89517.html" rel="external">"Overview of neuraxial anesthesia", section on 'Spinal-epidural hematoma (SEH)'</a>.)</p><p></p><p class="headingAnchor" id="H366954041"><span class="h2">Cancer</span><span class="headingEndMark"> — </span>For an individual receiving systemic cancer therapy, it is reasonable to check a platelet count. It may also be appropriate to check a PT and aPTT depending on nutritional status and other considerations that would interfere with oral intake and lead to vitamin K deficiency (mucositis, inability to eat, severe diarrhea). </p><p>Any active treatment should be reviewed for effects on bleeding risk, and the treating physician consulted. Certain chemotherapeutic and biologic agents should be held perioperatively due to effects on platelet function. <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">Ibrutinib</a> is an example. </p><p class="headingAnchor" id="H2368021278"><span class="h2">Liver disease</span><span class="headingEndMark"> — </span>(See  <a class="medical medical_review" href="/z/d/html/1234.html" rel="external">"Assessing surgical risk in patients with liver disease"</a>.)</p><p class="headingAnchor" id="H2424825982"><span class="h2">Kidney disease</span><span class="headingEndMark"> — </span>(See  <a class="medical medical_review" href="/z/d/html/1899.html" rel="external">"Medical management of the dialysis patient undergoing surgery"</a>.)</p><p class="headingAnchor" id="H676163856"><span class="h2">Children</span><span class="headingEndMark"> — </span>Children with bleeding disorders may have a negative bleeding history because they have not experienced bleeding challenges such as dental extractions, surgeries, circumcision, or menses. (See <a class="local">'Bleeding history'</a> above.)</p><p>As a result, clinicians should be more attentive to the child's history of less severe bleeding and to any family history of bleeding, bleeding disorders, or unexplained iron deficiency. </p><p class="headingAnchor" id="H1560663477"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/126589.html" rel="external">"Society guideline links: Preoperative medical evaluation and risk assessment"</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk assessment</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bleeding history</strong> – The patient's personal bleeding history and family history of bleeding disorders are essential to the preoperative evaluation. An easy-to-use bleeding assessment tool from the International Society of Thrombosis and Hemostasis (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fbleedingscore.certe.nl%2F&amp;token=Nn2kz6P9LalXZBakWq4EFVy%2FtKzfMxWmVZgnncoM9zqnY8WwoOfYCEf5tSBri%2Fvl&amp;TOPIC_ID=1315" target="_blank">ISTH-BAT</a>) can be completed by a member of the care team in a few minutes. Scores indicating abnormal bleeding are presented above. (See <a class="local">'Bleeding history'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Examination</strong> – Findings of a possible bleeding disorder include petechiae, ecchymosis or hemosiderin staining, suggestive of prior bleeding; signs of collagen-vascular disorders; hepatomegaly or splenomegaly heart murmurs; and signs of vitamin C deficiency (gingivitis, loose teeth, perifollicular purpura, and corkscrew hairs). (See <a class="local">'Examination'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Surgical procedure</strong> – The table summarizes bleeding risk for different procedures  (<a class="graphic graphic_table graphicRef86929" href="/z/d/graphic/86929.html" rel="external">table 2</a>). (See <a class="local">'Surgical bleeding risk'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory testing</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with negative bleeding history and family history</strong> – Routine coagulation testing prior to surgery is generally discouraged in unselected individuals due to the low likelihood of finding a bleeding disorder and the poor predictive value of standard coagulation tests. We reserve testing for individuals with a personal or family history of a bleeding disorder, comorbidity that impairs hemostasis, receiving an anticoagulant, or undergoing a high-risk procedure (neurosurgery, open cardiac or major vascular procedure). There is no role for the bleeding times. (See <a class="local">'Avoid routine testing in unselected individuals'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with suspected bleeding disorder</strong> – Testing starts with prothrombin time (PT), activated partial thromboplastin time (aPTT), and platelet count, with subsequent testing based on abnormal initial results  (<a class="graphic graphic_table graphicRef79969" href="/z/d/graphic/79969.html" rel="external">table 3</a>). Results may be normal in some bleeding disorders, and other testing may be indicated, including factor levels, von Willebrand disease (VWD) screening tests, platelet function tests, and/or others. If there is a known familial disorder, specific testing for that disorder is appropriate. A prolonged aPTT requires further investigation but does not necessarily imply the presence of a bleeding disorder. (See <a class="local">'Testing for people with a suspected bleeding disorder'</a> above and  <a class="medical medical_review" href="/z/d/html/5936.html" rel="external">"Approach to the child with bleeding symptoms"</a> and  <a class="medical medical_review" href="/z/d/html/1367.html" rel="external">"Approach to the adult with a suspected bleeding disorder"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Special populations</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Known bleeding disorder or anticoagulation</strong> – Preoperative planning should involve the patient's hematologist or other specialist managing their disorder or anticoagulation. Patients with known bleeding disorders will often have written plans for hemostatic management with them in case of severe or unexpected bleeding. (See <a class="local">'Known bleeding disorder or antithrombotic agent'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cancer</strong> – It is reasonable to check a platelet count, and PT and aPTT may be appropriate. Active treatment should be reviewed for effects on bleeding risk, and the treating physician consulted. Certain agents should be held perioperatively such as <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">ibrutinib</a>. (See <a class="local">'Cancer'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Liver or kidney disease</strong> – (See  <a class="medical medical_review" href="/z/d/html/1234.html" rel="external">"Assessing surgical risk in patients with liver disease"</a> and  <a class="medical medical_review" href="/z/d/html/1899.html" rel="external">"Medical management of the dialysis patient undergoing surgery"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Children</strong> – Children are more challenging to evaluate because they may have had fewer bleeding challenges. (See <a class="local">'Children'</a> above.)</p><p></p><p class="headingAnchor" id="H2284535860"><span class="h1">ACKNOWLEDGMENTS</span></p><p>The UpToDate editorial staff acknowledges Steven Coutre, MD (deceased), who contributed to an earlier version of this topic review.</p><p>The UpToDate editorial staff acknowledges Lawrence LK Leung, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">ISTH-SSC Bleeding Assessment Tool. Scientific and Standardization Committee. Available at: https://bleedingscore.certe.nl/ (Accessed on January 14, 2023).</li><li><a class="nounderline abstract_t">Rodeghiero F, Tosetto A, Abshire T, et al. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost 2010; 8:2063.</a></li><li><a class="nounderline abstract_t">Elbatarny M, Mollah S, Grabell J, et al. Normal range of bleeding scores for the ISTH-BAT: adult and pediatric data from the merging project. Haemophilia 2014; 20:831.</a></li><li><a class="nounderline abstract_t">Doherty D, Grabell J, Christopherson PA, et al. Variability in International Society on Thrombosis and Haemostasis-Scientific and Standardization Committee endorsed Bleeding Assessment Tool (ISTH-BAT) score with normal aging in healthy females: contributory factors and clinical significance. J Thromb Haemost 2023; 21:880.</a></li><li><a class="nounderline abstract_t">Moenen FCJI, Nelemans PJ, Schols SEM, et al. The diagnostic accuracy of bleeding assessment tools for the identification of patients with mild bleeding disorders: A systematic review. Haemophilia 2018; 24:525.</a></li><li><a class="nounderline abstract_t">Patel JJ, Mundi MS, Hurt RT, et al. Micronutrient Deficiencies After Bariatric Surgery: An Emphasis on Vitamins and Trace Minerals [Formula: see text]. Nutr Clin Pract 2017; 32:471.</a></li><li><a class="nounderline abstract_t">Chee YL, Crawford JC, Watson HG, Greaves M. Guidelines on the assessment of bleeding risk prior to surgery or invasive procedures. British Committee for Standards in Haematology. Br J Haematol 2008; 140:496.</a></li><li><a class="nounderline abstract_t">Cosmi B, Alatri A, Cattaneo M, et al. Assessment of the risk of bleeding in patients undergoing surgery or invasive procedures: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thromb Res 2009; 124:e6.</a></li><li><a class="nounderline abstract_t">Devine KJ, Diorio C, Richman SA, et al. Guideline for Children With Cancer Receiving General Anesthesia for Procedures and Imaging. J Pediatr Hematol Oncol 2022; 44:e859.</a></li><li><a class="nounderline abstract_t">Committee on Standards and Practice Parameters, Apfelbaum JL, Connis RT, et al. Practice advisory for preanesthesia evaluation: an updated report by the American Society of Anesthesiologists Task Force on Preanesthesia Evaluation. Anesthesiology 2012; 116:522.</a></li><li><a class="nounderline abstract_t">Hanna V, Popovic MM, El-Defrawy S, et al. Preoperative evaluations for ophthalmic surgery: A systematic review of 48,869 eyes. Surv Ophthalmol 2023; 68:526.</a></li><li><a class="nounderline abstract_t">Biron C, Mahieu B, Rochette A, et al. Preoperative screening for von Willebrand disease type 1: low yield and limited ability to predict bleeding. J Lab Clin Med 1999; 134:605.</a></li><li><a class="nounderline abstract_t">Liu Q, Zhang Y, Liu Y. Preoperative thromboelastography in the prediction of post-tonsillectomy hemorrhage by coblation tonsillectomy: a post-hoc analysis. Ann Saudi Med 2022; 42:377.</a></li><li><a class="nounderline abstract_t">Li X, Wu J, Zhang S, et al. Perioperative Coagulation Profile with Thromboelastography in Aspirin-Treated Patients Undergoing Posterior Lumbar Fusion. Pain Physician 2020; 23:E619.</a></li><li><a class="nounderline abstract_t">Ng KF, Lawmin JC, Tsang SF, et al. Value of a single preoperative PFA-100 measurement in assessing the risk of bleeding in patients taking cyclooxygenase inhibitors and undergoing total knee replacement. Br J Anaesth 2009; 102:779.</a></li><li><a class="nounderline abstract_t">Eisenberg JM, Clarke JR, Sussman SA. Prothrombin and partial thromboplastin times as preoperative screening tests. Arch Surg 1982; 117:48.</a></li><li><a class="nounderline abstract_t">Kaplan EB, Sheiner LB, Boeckmann AJ, et al. The usefulness of preoperative laboratory screening. JAMA 1985; 253:3576.</a></li><li><a class="nounderline abstract_t">Houry S, Georgeac C, Hay JM, et al. A prospective multicenter evaluation of preoperative hemostatic screening tests. The French Associations for Surgical Research. Am J Surg 1995; 170:19.</a></li></ol></div><div id="topicVersionRevision">Topic 1315 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://bleedingscore.certe.nl/" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : ISTH-SSC Bleeding Assessment Tool. Scientific and Standardization Committee. Available at: https://bleedingscore.certe.nl/ (Accessed on January 14, 2023).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20626619" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25196510" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Normal range of bleeding scores for the ISTH-BAT: adult and pediatric data from the merging project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36696194" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Variability in International Society on Thrombosis and Haemostasis-Scientific and Standardization Committee endorsed Bleeding Assessment Tool (ISTH-BAT) score with normal aging in healthy females: contributory factors and clinical significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29873431" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The diagnostic accuracy of bleeding assessment tools for the identification of patients with mild bleeding disorders: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28609642" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Micronutrient Deficiencies After Bariatric Surgery: An Emphasis on Vitamins and Trace Minerals [Formula: see text].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18275427" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Guidelines on the assessment of bleeding risk prior to surgery or invasive procedures. British Committee for Standards in Haematology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19740528" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Assessment of the risk of bleeding in patients undergoing surgery or invasive procedures: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35235547" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Guideline for Children With Cancer Receiving General Anesthesia for Procedures and Imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22273990" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Practice advisory for preanesthesia evaluation: an updated report by the American Society of Anesthesiologists Task Force on Preanesthesia Evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36572226" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Preoperative evaluations for ophthalmic surgery: A systematic review of 48,869 eyes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10595788" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Preoperative screening for von Willebrand disease type 1: low yield and limited ability to predict bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36444922" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Preoperative thromboelastography in the prediction of post-tonsillectomy hemorrhage by coblation tonsillectomy: a post-hoc analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33185380" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Perioperative Coagulation Profile with Thromboelastography in Aspirin-Treated Patients Undergoing Posterior Lumbar Fusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19411670" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Value of a single preoperative PFA-100 measurement in assessing the risk of bleeding in patients taking cyclooxygenase inhibitors and undergoing total knee replacement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7055424" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Prothrombin and partial thromboplastin times as preoperative screening tests.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3999339" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The usefulness of preoperative laboratory screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7793487" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : A prospective multicenter evaluation of preoperative hemostatic screening tests. The French Associations for Surgical Research.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
